By [Author Name/CRI Correspondent]
On August 27–28, 2026, the scientific community gathered not merely for a conference, but for a profound celebration of a life’s work. The Rudensky Symposium on Immunity, Inflammation, and Tolerance, held to mark the 70th birthday of Dr. Alexander “Sasha” Rudensky of Memorial Sloan Kettering Cancer Center (MSKCC), served as a powerful testament to the influence of one of immunology’s most respected figures.
For two days, the symposium acted as a bridge between the past and the future of biomedical research. It convened a "who’s who" of immunology—former trainees who have gone on to lead their own labs, longtime collaborators, and colleagues whose intellectual journeys have been intertwined with Dr. Rudensky’s for decades. While the event celebrated a personal milestone, its core objective remained the advancement of human knowledge, blending rigorous scientific inquiry with heartfelt reflections on the mentorship that has fueled the field for generations.
The Foundation: A Decades-Long Commitment to Basic Science
The Cancer Research Institute (CRI) has stood as a pillar of support for Dr. Rudensky’s research for over 20 years. This partnership is emblematic of the CRI’s broader mission: to fund foundational immunology with the foresight that such knowledge is the prerequisite for conquering cancer.
Dr. Rudensky’s contributions to the field are foundational. In 2015, he was awarded the prestigious CRI William B. Coley Award for his pioneering work on regulatory T cells (Tregs). These specialized immune cells act as the body’s "brakes," restraining excessive immune responses and preventing the autoimmune destruction of healthy tissues. By elucidating the mechanisms by which Tregs function, Dr. Rudensky provided the scientific community with a critical map of how the immune system maintains homeostasis—and how it can be manipulated to fight malignant disease.
The symposium underscored that the CRI’s investment in basic science is not just an investment in a specific project, but in a lineage of thinkers. Over a dozen CRI-funded fellows have passed through the Rudensky lab, carrying his rigorous approach to inquiry into their own independent careers.
The Interplay of Tissue Balance and Cancer
A recurring theme throughout the symposium was the symbiotic relationship between tissue repair, the gut microbiome, and cancer progression. Scientists presented evidence suggesting that the same mechanisms the body uses to heal a wound or maintain a stable gut environment are often hijacked by tumors to facilitate growth and immune evasion.
Insights from Tissue Maintenance
The symposium opened by shifting the focus away from cancer toward the broader principles of tissue biology. Dr. Ruslan Medzhitov, a CRI scientist and 2003 Coley Awardee, presented compelling research on how stressed cells recruit macrophages—not just to fight infection, but to act as a cellular "maintenance crew." These macrophages remove damaged proteins and cellular "garbage," ensuring that tissues remain healthy.
This concept of immune cells as architects of tissue health was further explored by 2024 Coley Award recipients Dr. Diane Mathis and Dr. Christophe Benoist. Dr. Mathis detailed how specific Treg populations facilitate muscle repair and limit scarring, while Dr. Benoist provided insights into how the molecular targets recognized by Tregs dictate their specific functional identity.
The implications for oncology are clear: the immune system’s role in tissue maintenance is a double-edged sword. If the system is too restrained, autoimmunity occurs. If it is too active in a tumor microenvironment, it may inadvertently protect cancer cells from destruction.
Chronology: From Preclinical Discovery to Future Therapeutics
The scientific program followed a logical progression: moving from the cellular "garbage" of healthy tissue to the earliest signs of oncogenesis, and finally to the complex, systemic ecosystems that define advanced cancer.
The Earliest Stages: Immunosurveillance
Dr. Richard A. Flavell, a 2012 Coley Awardee, presented findings on the earliest stages of cancer development. By studying mutant intestinal stem cells in mouse models, his team observed that even before a tumor is visible, the immune system is actively "screening" abnormal cells.
When cells carrying the BRAF mutation—a common driver of cancer—were introduced, the immune system successfully eliminated a large proportion of them. However, when these mutant cells lost the ability to communicate with T cells, they gained a dangerous survival advantage, allowing them to outcompete healthy neighbors. This suggests that the immune system is not just a responder to established tumors, but a participant in the evolutionary process that determines whether a mutation becomes a cancer or is suppressed in its infancy.
The Inflammation-Cancer Axis
Dr. Julien C. Marie expanded on this by examining the role of TGF-β, a regulatory signaling molecule. His research demonstrated that when this signal is disrupted in intestinal Th17 cells, these cells adopt a persistently inflammatory state that leads to DNA damage and, eventually, tumor development. The fact that restoring these signals could reverse the inflammatory damage suggests that the body’s "pro-cancer" inflammatory programs may be more flexible and reversible than previously thought.
Supporting Data: The Wider Ecosystem of the Tumor
As the symposium moved toward the topic of advanced disease, the focus shifted to the "neighborhoods" in which tumors live.
The Gut-Cancer Connection
Dr. Dan Littman, a CRI SAC member and 2016 Coley Awardee, provided a detailed look at how the gut microbiome influences the success of systemic immunotherapy. His work has shown that gut bacteria serve as "trainers" for T cells, directly affecting how well a patient might respond to checkpoint blockade therapy. This research highlights the systemic nature of immunity; an immune response triggered in the gut can have profound downstream effects on a tumor located elsewhere in the body.
Disrupting the Tumor Microenvironment
Dr. Paula D. Bos presented findings on the physical and cellular scaffolding of breast cancer. She demonstrated that Tregs don’t just suppress T cells directly; they also influence macrophages and the collagen fibers surrounding a tumor. By temporarily depleting these Tregs in mouse models, her team observed a shift in macrophage behavior and a physical restructuring of the tumor environment, which ultimately reduced the tumor’s ability to metastasize.
Similarly, Dr. Nicholas Arpaia explored how fibroblasts—the cells that provide structural support to tissues—can be "recruited" by tumors to create immune-suppressive neighborhoods. His work, which included a collaboration with CRI Lloyd J. Old STAR Dr. Tal Danino, utilized engineered bacteria to deliver therapeutics directly into the tumor. This approach aims to solve one of modern oncology’s greatest hurdles: how to modulate the immune system locally, where it is needed, without causing systemic side effects.
Implications for Future Cancer Care
The symposium was a masterclass in the "ripple effect" of scientific discovery. The researchers in attendance—many of whom were mentored by Dr. Rudensky—are now the ones shaping the field’s future.
The key takeaway from the two-day event was the necessity of maintaining a "basic science first" mindset. Many of the strategies discussed—such as manipulating macrophages to prevent metastasis or using engineered bacteria to modulate the microenvironment—did not begin as cancer treatments. They began as fundamental questions about how tissues stay in balance.
For the Cancer Research Institute, this event was a celebration of a 70-year mission. By funding the "people" behind the science, the CRI ensures that when a brilliant mind like Dr. Rudensky asks a difficult question about immune tolerance, it leads to a cascade of discoveries that eventually arrive at the bedside of a patient.
Conclusion: A Legacy of Mentorship
The Rudensky Symposium was more than a technical exchange of data; it was a humanizing look at the scientific process. The sight of generations of researchers, from newly minted PhDs to senior leaders, gathered to honor their mentor provided a tangible sense of the "scientific family."
As the field of cancer immunology moves toward an era of increasingly personalized, precision medicine, the lessons of the Rudensky Symposium remain vital. Progress in cancer care does not happen in a vacuum. It is built upon a foundation of rigorous disagreement, shared curiosity, and the long-term support of individuals who are willing to pursue questions whose clinical relevance may not be obvious at first glance.
In honoring Dr. Rudensky, the community didn’t just look back at his achievements—they affirmed their collective commitment to the future of discovery. As the symposium concluded, it was clear that the work of understanding immunity is far from finished, but in the hands of the generation he trained, the path forward is as bright as it has ever been.
